



CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION

(This code is being adopted in satisfaction of Regulation 8 (1) of the SEBI (Prohibition of Insider Trading) Regulations, 2015)

A. OBJECTIVE OF THE CODE

This code is applicable to all disclosures of UPSI by Finecure Pharmaceuticals Limited, (hereinafter referred to as the “Company”) its subsidiaries, associates and the companies under the same management.

B. UNIFORM AND UNIVERSAL DISSEMINATION OF UNPUBLISHED PRICE SENSITIVE INFORMATION

The Company has adopted a Disclosure Policy. The Disclosure Policy defines Material Event and Material Information. Prompt public disclosure of Unpublished Price Sensitive Information (USPI) shall be done no sooner than credible and concrete information comes into being in order to make such information generally available.

(i) "**Material Events**" shall mean events that a reasonable stakeholder dealing with the Company would consider important in deciding to engage and deal with the Company, its products and services and in its securities.

Provided that whether any particular information could be considered Material by a reasonable stakeholder depends on specific circumstances existing at a particular point of time.

(ii) "**Material Information**" shall mean Material Events meeting the requirements of the Disclosure Policy.

When a Material event or Material Information triggers disclosure, the Company shall promptly furnish the Material Information to all stock exchanges where its Securities are listed. Information published on the website of a stock exchange, would ordinarily be considered generally available information.

The information released by the Company to the stock exchanges may also be released to the press for wider circulation. The information released by the Company to the stock exchanges may also be hosted on the Company website <http://www.finecurepharma.com> for wider circulation.

C. Interactions with Analysts, Investors and Research Personnel

The Company shall ensure that the following guidelines are followed while dealing with analysts and institutional investors.

In order to maintain a transparent and effective two-way communication between a Company, the financial community, the Management shall interact with equity research analysts, investors and other members of the investing community from time to time.

During these interactions, the Company will ensure that no UPSI is disclosed selectively to any one or group of research analysts or investors, to the disadvantage of other stakeholders. In structured communication events, the Company may make arrangements to ensure that the interactions at the event are available to the public simultaneously. This simultaneous access may be achieved by making

Registered Office :

612 to 615, Anand Mangal Complex III, Nr. Parimal Garden,
Rajnagar Club Lane, Ellisbridge, Ahmedabad - 380006, Gujarat, India.

+91-79-4903 0405 +91-79-4903 0400 www.finecurepharma.com

Corporate Office :

306, 3rd Floor, 3rd Eye One Complex, Opp. Havmor Restaurant,
Panchvati, C.G. Road, Ahmedabad -380006, Gujarat, India

+91-79-4903 0903 +91-79-4903 0915



arrangements for simultaneous audio broadcast of such interaction/ calls over the phone or internet or suitable media with due notice of such interaction. Recording of the proceedings in suitable media will be made available on the official website for a period of 5 years.

Handling of unanticipated questions

The Company shall promptly and carefully deal with analysts' questions that raise material issues outside the intended scope of discussion. Unanticipated questions may be taken on notice and a considered response given later. If the answer includes UPSI, a public announcement shall be made before responding.

Medium of disclosure/dissemination

Disclosure and dissemination of information may be done through various media so as to achieve maximum reach and quick dissemination. All disclosures to the stock exchanges must be made promptly. The Company shall also disclose information through the use of its dedicated Internet website <http://www.finecurepharma.com>

Company's website

The Company's website (<http://www.finecurepharma.com>) may provide a means of giving a direct access to analyst briefing material, significant background information and questions and answers.

D. PROMPT DISSEMINATION OF UPSI THAT IS DISCLOSED SELECTIVELY

In the event of selective disclosure of UPSI, inadvertently or otherwise the Company shall respond promptly to ensure prompt dissemination of the UPSI as per clause B above.

The compliance officer and or chief investor relations officer shall respond promptly and fairly upon learning of the selective disclosure. In this context, rumors or media speculation (including quotes of unnamed persons) shall not be considered as selective disclosure

E. RESPONSE TO REGULATORY AUTHORITIES

The Company shall respond appropriately and fairly to queries on news reports and requests for verification of market rumours by regulatory authorities. The Company will endeavor to respond promptly to such requests.

F. OVERSEEING AND COORDINATING DISCLOSURE

The prime responsibility for overseeing and disclosure in the Company shall be on the Compliance Officer designated under the Code of Internal Procedures and Conduct For Prevention of Insider Trading of Finecure Pharmaceutical Limited.

The Compliance Officer shall be responsible for:

- i. Complying with continuous disclosure requirements;
- ii. Overseeing and coordinating disclosure of UPSI to stock exchanges, analysts, Shareholders and media;
- iii. Educating staff on disclosure policies and procedure.

Registered Office :

612 to 615, Anand Mangal Complex III, Nr. Parimal Garden,
Rajnagar Club Lane, Ellisbridge, Ahmedabad - 380006, Gujarat, India.

+91-79-4903 0405 +91-79-4903 0400 www.finecurepharma.com

Corporate Office :

306, 3rd Floor, 3rd Eye One Complex, Opp. Havmor Restaurant,
Panchvati, C.G. Road, Ahmedabad -380006, Gujarat, India

+91-79-4903 0903 +91-79-4903 0915



The Compliance Officer shall approve the disclosure of the information in advance.

The Compliance Officer is designated to deal with dissemination of information and disclosure of UPSI.

G. RESPONDING TO MARKET RUMOURS

All the stock exchanges where the securities of the Company are listed are required to be informed well in advance the name and address of the Compliance Officer to whom the exchanges may refer any market rumours for verification.

Such a communication to the stock exchanges may include fax number, telephone number and email id of the Compliance Officer.

On receipt of requests from any of the stock exchanges for verification of market rumours, the Compliance Officer shall ascertain the factual position and thereafter appropriately and fairly respond to such queries or requests.

At the time of making such response, the Compliance Officer may decide as to whether a public announcement is necessary for verifying or denying rumours and then make the disclosure.

H. HANDLING OF ALL UNPUBLISHED PRICE-SENSITIVE INFORMATION

The Company will handle all UPSI with internal personnel on a need-to-know basis and no UPSI shall be communicated to any person except for internal personnel's legitimate purposes, performance of duties or discharge of his or her legal obligations. The Company may form internal guidelines which shall contain appropriate Chinese Walls procedures and processes while sharing the UPSI on a need-to-know basis.

The information filed by Company with stock exchanges under a continuous disclosure requirement may be made available on the Company's website.

Registered Office :

612 to 615, Anand Mangal Complex III, Nr. Parimal Garden,
Rajnagar Club Lane, Ellisbridge, Ahmedabad - 380006, Gujarat, India.

+91-79-4903 0405 +91-79-4903 0400 www.finecurepharma.com

Corporate Office :

306, 3rd Floor, 3rd Eye One Complex, Opp. Havmor Restaurant,
Panchvati, C.G. Road, Ahmedabad -380006, Gujarat, India

+91-79-4903 0903 +91-79-4903 0915